New Cancer Drugs · global
RAS-targeted pancreatic cancer drug daraxonrasib approved in the US, extends survival in phase 3 trial
A randomized trial of 500 patients brings a strategy that blocks RAS signaling into treatment for metastatic pancreatic cancer. Median overall survival reached 13.2 months in the daraxonrasib group, but eligibility and toxicity management remain key to understanding this approval.
For patients whose pancreatic cancer has metastasized and continued to progress after treatment, a new drug option must answer a straightforward question: can it extend life? On August 26, 2026, the US Food and Drug Administration (FDA) approved Revolution Medicines’ daraxonrasib, under the brand name Rasonque. The randomized trial supporting the approval showed a clear survival benefit for this RAS inhibitor compared with chemotherapy.
The approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are not suitable for multidrug systemic therapy. However, participants in the pivotal trial were primarily patients whose disease had progressed after first-line treatment; the approved indication must still be distinguished from the population that directly generated the comparative evidence.
The phase 3 trial, named RASolute 302, was led by Brian Wolpin of Dana-Farber Cancer Institute and enrolled 500 patients across North America, Europe, and Asia. Participants were randomly assigned to receive daraxonrasib or standard chemotherapy of the physician’s choice. Median overall survival in the overall population was 13.2 months and 6.7 months, respectively, with a hazard ratio for death of 0.40. This is a statistical comparison between two groups of patients and cannot be interpreted to mean that every patient will live longer by the same amount of time.
Daraxonrasib’s mechanism of action also illustrates a new path in RAS drug development. According to Dana-Farber, it acts like a “molecular glue,” working with the intracellular protein cyclophilin A to block RAS signaling. This allows treatment to directly interfere with an important mechanism that drives cancer cell growth; the institute also identifies it as the first approved RAS-targeted therapy for pancreatic cancer.
Beyond efficacy, the burden of treatment cannot be overlooked. Common side effects listed by Dana-Farber include rash, inflammation of the mouth, nausea, and diarrhea. The FDA notes that the prescribing information includes warnings for skin and soft tissue toxicity, oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity. Oral administration offers convenience, but ongoing monitoring and management of adverse reactions remain necessary.
Background
RAS drug development in pancreatic cancer is advancing across different stages of treatment at the same time. Another drug, zoldonrasib, which targets RAS G12D, has moved toward a phase 3 trial in combination with chemotherapy as first-line treatment; the approval daraxonrasib has now secured is US marketing authorization for specific patients with metastatic disease. These are different drugs, and findings for one cannot be directly applied to the other.
This approval gives the RAS inhibition strategy a concrete result that can enter clinical use. However, it does not yet support the conclusion that the treatment is suitable for all patients with pancreatic cancer or can replace chemotherapy at every stage of treatment. Whether earlier use is beneficial, how different therapies should be sequenced, and how long the benefit can last will each require their own clinical evidence.